Iranian Knowledge-Based Firm Processes All Types of Immune, Blood Cells for Cancer Treatment
“Our company is a leading firm in production of advanced cellular products with the aim of providing cellular services based on immune cells, hematopoietic cells, and genetically modified cells,” said Marzieh Ebrahimi, the managing director of Kian Eimen Selloul company.
“In addition to having the approval of the Food and Drug Administration of Iran, our company is the first holder of the international medical equipment standard certificate ISO13485:2016 and the ISO9001:2015 for quality management system in the field of isolation of natural killer cells from peripheral blood for the purpose of cancer treatment and early detection of drug resistance in patients,” she added.
“The company also enjoys the necessary capability of processing all types of immune cells and blood cells for treatment, gene changes in blood cells with therapeutic purposes and providing consulting services,” Ebrahimi said.
She noted that haploidentical natural killer cell (NK) for cancer immunotherapy, off-the-shelf allogeneic NK cells for cancer immunotherapy, and tumor-specific anticancer drug sensitivity test kit are among the most important products of the company.
Ebrahimi reminded that 3D culture models and cell lethality test are also among the important services provided by her company.
In relevant remarks in November, a senior Iranian medical official announced that Iran is the third country in the world which has attained the technology for gene manipulation.
“Our country has been researching and working on stem cells for years but the most important branch of stem cells is genes and we should make further progress in this field,” Amir Ali Hamidiyeh, the secretary of the Stem Cell Technologies Development Headquarters of the Iranian Vice-Presidency for Science and Technology, told ANA.
He elaborated on Iran's capabilities in the field of regenerative medicine and gene therapy, and said, “This technology exists only in two countries of the world, and Iran is the third country that has achieved this technology.”
Hamidiyeh underlined that Iran will stand among the countries that can work on genome editing and intracellular manipulations in the future.
He added that in the past few months, a number of children with cancer completely recovered and returned to life with the help of gene therapy and gene modification.
Iranian specialists and physicians for the first time in the country succeeded in treating a child with leukemia using gene therapy.
A team of Iranian doctors presented a unique method called ‘CAR T-cell therapy’ for the treatment of children with cancer using gene therapy.
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy because it involves altering the genes inside T cells to help them attack cancer.
CAR T-cell is the newest method for cancer treatment in the world, which has reached the final stage with the efforts of an Iranian knowledge-based company, Hamidiyeh said.
4155/v
